Fausto Biancari, Hannu Romppanen, Mikko Savontaus, Antti Siljander, Timo Mäkikallio, Olli-Pekka Piira, Jarkko Piuhola, Viivi Vilkki, Antti Ylitalo, Tuija Vasankari, Juhani K.E. Airaksinen, Matti Niemelä, MANTA versus ProGlide vascular closure devices in transfemoral transcatheter aortic valve implantation, International Journal of Cardiology, Volume 263, 2018, Pages 29-31, ISSN 0167-5273, https://doi.org/10.1016/j.ijcard.2018.04.065
MANTA versus ProGlide vascular closure devices in transfemoral transcatheter aortic valve implantation
|Author:||Biancari, Fausto1,2; Romppanen, Hannu3; Savontaus, Mikko1;|
1Heart Center, Turku University Hospital, University of Turku, Turku, Finland
2Department of Surgery, University of Oulu, Oulu, Finland
3Heart Center, Kuopio University Hospital, Kuopio, Finland
4Department of Cardiology, Oulu University Hospital, Oulu, Finland
|Online Access:||PDF Full Text (PDF, 0.2 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2019102134080
|Publish Date:|| 2019-10-21
Background: The MANTA system is a novel vascular closure device (VCD) and its safety and efficacy were compared to the ProGlide VCD in patients undergoing transfemoral transcatheter aortic valve implantation (TAVI).
Methods: This is a retrospective study including 222 patients who underwent transfemoral TAVI at three Finnish University Hospitals. The MANTA VCD was used in 107 patients and their outcome was compared with that of 115 patients in whom the arterial access was closed with the ProGlide VCD.
Results: VARC-2 VCD failure occurred less frequently in the MANTA cohort (3.7% vs. 7.8%, p = 0.378), but the difference did not reach statistical significance. When adjusted for the introducer outer diameter, the MANTA cohort had similar rates of VARC-2 major vascular complications (9.3% vs. 12.2%, adjusted: p = 0.456), VARC-2 life-threatening/disabling bleeding (9.3% vs. 6.1%, adjusted: p = 0.296) and need of invasive treatment of bleeding (4.7% vs. 7.0%, adjusted: p = 0.416) compared to the ProGlide cohort. Additional VCDs were more frequently needed in the ProGlide cohort (58.3% vs. 1.9%, p < 0.0001).
Conclusions: In patients undergoing transfemoral TAVI, the MANTA VCD showed a similar risk of VARC-2 vascular and bleeding complications compared to the ProGlide VCD, but it reduced significantly the need of additional VCDs for completion of hemostasis.
International journal of cardiology
|Pages:||29 - 31|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3126 Surgery, anesthesiology, intensive care, radiology
© 2018 Published by Elsevier B.V. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/.